Genomic Amplification of TBC1D31 Promotes Hepatocellular Carcinoma Through Reducing the Rab22A‐Mediated Endolysosomal Trafficking and Degradation of EGFR
Pengbo Cao,Hongxia Chen,Ying Zhang,Qi Zhang,Mengting Shi,Huihui Han,Xiaowen Wang,Liang Jin,Bingqian Guo,Rongjiao Hao,Xi Zhao,Yuanfeng Li,Chengming Gao,Xinyi Liu,Yahui Wang,Aiqing Yang,Chenning Yang,Anfeng Si,Hua Li,Qingfeng Song,Fuchu He,Gangqiao Zhou
DOI: https://doi.org/10.1002/advs.202405459
IF: 15.1
2024-09-02
Advanced Science
Abstract:Epidermal growth factor receptor (EGFR), rarely driven by oncogenic mutations ( 60%). Here, TBC1D31 is identified as a novel Rab GTPase activating protein to catalyze GTP hydrolysis for Rab22A, which mediates endolysosomal trafficking and degradation of EGFR, and proposes TBC1D31 as a novel actionable target for HCC patients with 8q24.13 amplification. Hepatocellular carcinomas (HCCs) are characterized by a vast spectrum of somatic copy number alterations (CNAs); however, their functional relevance is largely unknown. By performing a genome‐wide survey on prognosis‐associated focal CNAs in 814 HCC patients by an integrative computational framework based on transcriptomic data, genomic amplification is identified at 8q24.13 as a promising candidate. Further evidence is provided that the 8q24.13 amplification‐driven overexpression of Rab GTPase activating protein TBC1D31 exacerbates HCC growth and metastasis both in vitro and in vivo through activating Epidermal growth factor receptor (EGFR) signaling. Mechanistically, TBC1D31 acts as a Rab GTPase activating protein to catalyze GTP hydrolysis for Rab22A and then reduces the Rab22A‐mediated endolysosomal trafficking and degradation of EGFR. Notably, overexpression of TBC1D31 markedly increases the resistance of HCC cells to lenvatinib, whereas inhibition of the TBC1D31‐EGFR axis can reverse this resistance phenotype. This study highlights that TBC1D31 at 8q24.13 is a new critical oncogene, uncovers a novel mechanism of EGFR activation in HCC, and proposes the potential strategies for treating HCC patients with TBC1D31 amplification or overexpression.
materials science, multidisciplinary,nanoscience & nanotechnology,chemistry